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Background: Hypertension has a significant relevance as a cardiovascular risk factor. A consistent increase on
world’s Metabolic Syndrome (MetS) incidence has been associated with an epidemic cardiovascular risk in different
populations. Dislipidemia plays a major role determining the epidemic CV burden attributed to MetS. Apolipoprotein E
(ApoE) is involved on cholesterol and triglycerides metabolism regulation. Once ApoE polymorphism may influence
lipid metabolism, it is possible that it brings on individual susceptibility consequences for the development of MetS
and cardiovascular risk. The objective of the study is to measure the discriminatory power of ApoE polymorphism in
determining cardiovascular risk stratification based on the presence MetS in a cohort of hypertensive patients.
Methods: It was enrolled 383 patients, divided in two groups, classified by MetS presence (IDF criteria): Group 1: 266
patients with MetS (MetS +) and Group 2: 117 patients without Mets (MetS -). Patient’s data were collected by clinical
evaluation, physical exam, file reviews and laboratory testing. Polymorphic ApoE analysis was performed by PCR
amplification. Groups were compared on clinical and laboratory characteristics as well as allele and genotype
distribution towards ApoE polymorphism. Mets CVD prevalence was analysed according to E4 allele prevalence.
Results: The results evidenced 184 men (48%), 63,7% whites, 45,1% diabetics and 11,7% of patients were smokers.
Mean age was 64,0 ± 12,0 years. When genotypic distribution was analyzed, E3/3 genotype and E3 allele frequencies
were more prevalent. Among patients with MetS, we observed an independent association between CVD prevalence
and E4 allele frequency (OR 2.42 (1.17- 5.0, p < 0,05)). On the opposite direction, in those without MetS, there was lesser
CVD burden in E4 allele carriers (OR 0,14 (0,02-0,75)). These associations remained significant even after confounding
factor corrections.
Conclusions: The results presented demonstrate that the association between ApoE gene and CVD may be modulated
by the presence of MetS, with an increased CV burden observed among E4 allele carriers with the syndrome. On the
opposite way, E4 allele carriers without visceral obesity had lesser prevalence of CVD.
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Table 1 Population clinical and laboratory characteristics
based on MetS presence
Total MetS (+) MetS (−) p
(n = 266) (n = 117)
Men 184 (48.0%) 117 (43.9%) 67 (57.2%) < 0.05
Age (years) 64.0 ± 12.0 64.0 ± 11.7 63.7 ± 12.7 NS
White 244 (63.7%) 173 (65%) 71 (60.6%) NS
Weight (kg) 78.0 ± 44.4 82.1 ± 52.2 69.0 ± 13.7 < 0.05
BMI (kg/cm2) 29.3 ± 5.6 30.6 ± 5.2 26.5 ± 5.6 < 0.05
Waist (cm) 100.2 ± 13.8 104.5 ± 11.8 90.8 ± 13.1 < 0.05
DM 173 (45.1%) 144 (54.1%) 29 (24.7%) < 0.05
Dislipidemia 311 (81.2%) 229 (86%) 82 (70%) < 0.05
CVD 133 (34.7%) 101 (37.9%) 32 (27.3%) < 0.05
Sedentarism 302 (78.8%) 210 (78.9%) 92 (78.6%) NS
Smoking 45 (11.7%) 34 (12.7%) 11 (9.4%) NS
Alcohol 28 (7.3%) 18 (6.7%) 10 (8.5%) NS
Chol (mg/dl) 181.5 ± 40.0 181.5 ± 41.8 181.9 ± 36.2 NS
HDL-c (mg/dl) 46.6 ± 13.0 42.6 ± 9.9 55.7 ± 14.9 < 0.05
LDL-c (mg/dl) 105.0 ± 33.5 105.0 ± 35.1 105.4 ± 30.0 NS
TG (mg/dl) 151.2 ± 83.8 170.3 ± 83.7 109.7 ± 68.7 < 0.05
Cr (mg/dl) 1.46 ± 0,86 1.46 ± 0.89 1.44 ± 0,83 NS
U (mg/dl) 58.7 ± 31.3 58.9 ± 31.7 58.5 ± 31,0 NS
CRP (mg/dl) 0.56 ± 0.77 0.64 ± 0.86 0.39 ± 0.51 < 0.05
BMI: body max index; DM: diabetes mellitus; Chol: total cholesterol; HDL-C:
HDL cholesterol; LDL-c: LDL cholesterol; TG: triglycerides; Cr: creatinine;
U: urea; CRP: C reactive protein. p: <0,05 MetS (+) versus Mets (−); p: NS,
non significant.
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Hypertension has a worldwide prevalence estimated in 1
billion of people, an attributable mortality of 7,1 million of
deaths per year and a significant relevance as a cardiovas-
cular risk factor. Intrinsically related with hypertension,
visceral obesity, the main component of Metabolic Syn-
drome (MetS), significantly contribute to the reduction
of life expectancy. According to the World Health
Organization (WHO), 1,5 billion of people will be obese
in 2015 [1]. Regarded as a clinicopathological clustering
of metabolic disorders determining increased cardio-
vascular disease (CVD) risk, MetS has a polygenic in-
herence in which abdominal fat accumulation plays
pivotal role for such epidemic morbidity [2]. Although
a significant portion of CVD in MetS may be explained
by the presence of well-known risk factors, a significant
proportion remains unexplained possibly due to indi-
vidual genetic variability.
Among those individuals with MetS, dislipidemia and
its consequences (coronary artery disease, stroke and
others) are attributed to a conjunct and integrative ac-
tion between genetic and environmental factors. The
main lipoprotein abnormality related with MetS is low
concentration of HDL cholesterol and hypertriglyc-
eridemia. The characteristic components of the syndrome
are mostly determined by apolipoprotein E (ApoE) modu-
lation of atherogenic plasma Apo-B containing lipopro-
teins. In fact, ApoE is the main constituent of tg-rich
lipoprotein and genetic polymorphic variations of this
protein has been associated with CVD occurrence. Identi-
fication of genetic markers has clinical relevance in this
context, as for risk prediction as for adoption of thera-
peutic maneuvers.
Apo E has three different alleles (E2, E3 and E4) deter-
mining different and complex associations with clinical
phenotype expressions. In fact, epidemiological studies
suggested that E4 allele carriers were particularly predis-
posed to develop higher cholesterol levels and higher
coronary artery disease (CAD) mortality, meanwhile
others studies concluded E3 and E4 alellles presences
were associated with higher risk in men. Conversely,
Olivieri et al. [3] found a higher MetS prevalence
among E4 alelle carriers while Ferreira et al. [4] did not
observe such association of this allele with MetS or
hypertension.
Due to the its polymorphic characteristic determining
diversity in clinical expression, we speculate whether
Apo E genotype could influence diversely on CVD bur-
den based on the presence of MetS on specific high risk
population. With this regard, the aim of this study is to
measure the discriminatory power of ApoE genetic
polymorphism in determining the cardiovascular risk
stratification based on the presence MetS in a cohort of
hypertensive patients.Results
At the end of the study, 383 patients were analyzed. Popu-
lation clinical and laboratory characteristics are shown on
Table 1. As depicted on Table 1, 184 patients were men
(48%), 63.7% whites, 45.1% diabetics,11.7% of patients
were smokers and mean age was 64,0 ± 12,0 years. Pa-
tients were classified by MetS diagnosis. MetS (+) group
showed higher prevalence of men and, as expected,
weight, BMI, waist, CRP, dislipidemia (including lower
HDL-cholesterol and triglycerides levels) and CVD preva-
lence were higher in this group when comparing with
Mets (−) group.
As shown on Table 2, no statistical difference was
identified between groups when genotypes and alleles
distribution, stratified by race, were analyzed.
In genotypic distribution analysis, it was identified that
E3/3 genotype and E3 allele frequencies were more
prevalent. E4/3 genotype and E4 allele were the second
most frequent genotype and allele, respectively. This
prevalence, even not statistically significant, remained
similar independently of MetS presence (Table 3).
Analyses of E2 and E3 allleles clinical and laboratory
characteristics showed no statistical difference between
allele (+) versus allele (−) groups (data not shown).
Table 2 ApoE genotypes and alleles distribution based on
race
White (N = 237) Black (N = 68) Others (N = 78) p
E4/4 4 (1.7%) 2 (2.9%) 1 (1.3%) NS
E4/3 41 (17.2%) 7 (10.1%) 8 (10.3%) NS
E3/3 167 (71%) 51 (75.4%) 60 (76.8%) NS
E3/2 20 (8.0%) 6 (8.7%) 8 (10.3%) NS
E4/2 5 (2.1%) 2 (2.9%) 1 (1.3%) NS
E2 allele 24 (10.1%) 8 (11.6%) 9 (11.5%) NS
E3 allele 227 (96.2%) 63 (94.2%) 78 (97.4%) NS
E4 allele 50 (21%) 11 (15.9%) 10 (12.8%) NS
Genotypes: E4/4, E 4/3, E 3/3, E 3/2, E 4/2. Alleles: 2,3 and 4. p: NS, non
significant.
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frequency, clinical laboratory results evidenced, in MetS
(+) patients, higher CVD prevalence in allele E4 carriers,
meanwhile, in patients without MetS diagnosis, allele E4
presence was associated with lesser CVD prevalence
(Table 4).
These associations remained statistically significant
even after confounding agents adjustment like age, sex,
smoking, DM, total cholesterol, HDL-cholesterol and
LDL-cholesterol (Table 5).Discussion
Our study of ApoE genetic polymorphism on cardiovas-
cular stratification in a cohort of hypertensive Mets (+)
patients evidenced higher CVD prevalence among those
E4 allele carriers patients. However, CVD prevalence in
Mets (−) E4 allele carriers was lower. This association
can be influenced by the presence of traditional cardio-
vascular risk factors [5].
In Chu et al. [6], E2 allele was described as the rarest
allele in several races, and E4 allele was described as
15% in white and 22% in non hispanic black. The mostTable 3 ApoE genotypes and alleles distribution based on
MetS presence
Total MetS (+) Mets (−) p
(n = 266) (n = 117)
E4/4 7 (1.8%) 5 (1.9%) 2 (1.7%) NS
E4/3 56 (14.6%) 37 (13.9%) 19 (16.2%) NS
E3/3 278 (72.6%) 197 (73.3%) 85 (70.9%) NS
E3/2 34 (8.9%) 24 (9.0%) 10 (8.5%) NS
E4/2 8 (2.1%) 5 (1.9%) 3 (2.6%) NS
E2 allele 42 (11.0%) 29 (10.9%) 13 (11.1%) NS
E3 allele 368 (96.1%) 256 (96.2%) 112 (95.7%) NS
E4 allele 71 (18.5%) 47 (17.7%) 24 (20.5%) NS
Genotypes: E4/4, E 4/3, E 3/3, E 3/2, E 4/2. Alleles: 2,3 and 4. p: NS, non
significant.common genotypes E2/3, E3/3 and E3/4 amounted 95%
of white genotypes and 89% of blacks. In our study,
similarly to the literature, E2 allele was less prevalent
and E4 allele was present 21% of whites and 15,9% of
black patients. E3/2, E3/3 and E4/3 genotypes amounted
96,2% in white and 94,2% in black. When we analyzed
the alleles and genotypes distribution stratified by race,
we did not find statistical differences between groups.
In comparisons looking for risk determination, E3/3
homozygote genotype has been used as reference. In
general, E2 allele presence is associated to lower choles-
terol and LDL-cholesterol levels [7] and triglycerides ele-
vation [8]. On the other hand, E4 allele is associated
with total cholesterol and LDL-cholesterol elevation.
These effects were demonstrated in several populations,
including pediatrics ones [9]. However, we did not find
clinical and laboratory differences in patients stratified
by alleles 2, 3 and 4 presence (data not shown). The
genotypic and allelic distribuition were similar to the ob-
served in other publications [10]. E3/3 genotype was the
most prevalent genotype globally and between Mets (+)
and MetS (−) groups, as well as when E3 allele was
analysed.
Epidemiological studies analysed ApoE polymorphism
impact on cardiovascular disease. Eichner et al. [11] and
Lehtinen et al. [12] suggested that E4 allele carriers were
particularly predisposed to develop coronary lesions or to
possess elevated risk of CAD death. The authors suggest
that this could be a consequence of lipoprotein metabol-
ism dysfunction associated to E4 isoform, with elevation
of total cholesterol and triglycerides levels [13]. More re-
cently, similar results was described by Chaudhary et al.
[14], in a type 2 diabetes mellitus population. Schiele et al.
[15], studying northern europe populations with higher
cholesterol levels and higher CVD mortality have
shown higher E4 alelle presence also. Hixson et al. [16]
and Ilveskoski et al. [17], studying vascular necropsy alter-
ations, showed more atherosclerotic lesions in E4 allele
carriers, independently of total cholesterol levels. On the
other hand, angiographic studies did not evidenced higher
CAD risk in E4 allele carriers [18].
In MONICA study [19], E4 allele frequency elevation
of 0,01 was associated to a rise on CAD death of 24,5
per 100.000 patients. In 4S study [20], E4 allele carriers
presented 80% higher death risk after myocardial infarc-
tion, in comparison with other patients. Lahoz et al. [21]
concluded that E2 and E4 allele presences were associ-
ated with higher cardiovascular risk in men. The authors
argued that E4 allele determine higher risk partly due to
the lipid alterations that it brings on.
In our study, although E4 allele had not been associated
with higher MetS prevalence neither conferred higher
cardiovascular disease risk on study population, when
analyzing exclusively MetS population, we identified an
Table 4 Population clinical and laboratory characteristics according to Mets diagnosis based on ApoE E4 allele
presence
MetS (+) n = 266 MetS (−) n = 117
E4 allele (−) E4 allele (+) N E4 allele (−) E4 allele (+) N
Men 92 (42.0%) 21 (44.7%) NS 49 (52.7%) 14 (58.3%) NS
Age (years) 64.4 ± 11.3 62.5 ± 12.5 NS 63.1 ± 12.7 64.8 ± 13.1 NS
White 131 (59.8%) 37 (78.7%) < 0,05 55 (59.8%) 13 (54.2%) NS
Weight (kg) 82.8 ± 57.7 79.0 ± 16.8 NS 68.9 ± 14.0 69.5 ± 14.0 NS
BMI (kg/cm2) 30.6 ± 4.9 30.5 ± 6.4 NS 26.6 ± 5.8 26.6 ± 5.3 NS
Waist (cm) 104.4 ± 11.6 104.6 ± 13.5 NS 91.1 ± 13.4 91.0 ± 13.0 NS
DM 114 (52.1%) 25 (53.2%) NS 21 (22.8%) 6 (25.0%) NS
Dislipidemia 184 (84.0%) 41 (87.2%) NS 63 (67.7%) 16 (66.7%) NS
CVD 75 (34.7%) 24 (51.1%) < 0,05 27 (30.0%) 2 (8.3%) < 0.05
Sedentarism 171 (80.7%) 34 (75.6%) NS 69 (76.7%) 20 (87.0%) NS
Smoking 30 (14.0%) 4 (8,5%) NS 8 (8.7%) 3 (13.6%) NS
Alcohol 16 (7.5%) 2 (4,3%) NS 7 (7.7%) 3 (13.0%) NS
Chol (mg/dl) 182.2 ± 42.2 179.4 ± 41.5 NS 186.5 ± 37.1 170.0 ± 27.5 < 0.05
HDL-c (mg/dl) 43.0 ± 9.8 40.5 ± 10.4 NS 56.2 ± 15.7 52.9 ± 11.4 NS
LDL-c (mg/dl) 105.9 ± 35.4 104.1 ± 33.2 NS 109.6 ± 31.3 93.3 ± 20.5 < 0.05
TG (mg/dl) 168.2 ± 80.1 184.3 ± 94.3 NS 108.5 ± 69.8 117.8 ± 71.6 NS
Cr (mg/dl) 1.48 ± 0.92 1.36 ± 0.70 NS 1.43 ± 0.77 1.51 ± 1.09 NS
U (mg/dl) 59.6 ± 31.9 55.4 ± 31.6 NS 57.9 ± 29.7 60.2 ± 36.2 NS
CRP (mg/dl) 0.63 ± 0.80 0.61 ± 0.81 NS 0.41 ± 0.52 0.32 ± 0.49 NS
BMI: body mass index; DM: diabetes mellitus; Chol: total cholesterol; HDL-C: HDL cholesterol; LDL-c: LDL cholesterol; TG: Triglycerides; Cr: creatinine; U: urea; CRP: C
reactive protein C. p: NS, non significant.
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hand, when we analysed Mets (−) population, we identi-
fied higher prevalence of E4 allele in CVD negative than
CVD positive patients. These associations remained sig-
nificant even after correction for confounding factors.
This result seem to suggest that E4 allele capability to de-
termine higher prevalence of CVD would be entailed by
MetS presence, corroborating Apolipoprotein E modula-
tion of atherogenic plasma Apo-B containing lipoproteins
seen in this disorder. Some studies have described a con-
troversial role of E4 allele polymorphism in different pop-
ulations, some depositing a protector role and others an
adverse outcome related with its presence. Yan et al. [22]
described a protector polymorphism effect on the devel-
opment of foam liver disease; ARIC study researchers
identified an association of this polymorphism and lower
risk of development CKD, acting as an effective protector
factor of diabetic nephropathy in type 2 diabetes mellitus
[23]. Other publications have demonstrated lower risk of
CKD progression also [24], particularly in elderly [8]. Con-
versely, E4 allele have been associated with a more un-
favorable metabolic profile in one study [25] and,
according to Song et al. [26], it was associated with higher
CAD risk. Olivieiri et al. [3] described E4 allele prevalence
2-fold higher on Mets (+) than MetS (−) population.Nevertheless, some studies did not showed the same asso-
ciation and the results were not representative of general
population.
One possible explanation would be that the ApoE E4
allele polymorphism could be conditioned to other clin-
ical variables presence, conferring, as along in our study,
to MetS, an apolipoprotein modulator paper. This result
suggests an association of this clinical condition in rela-
tion to ApoE polymorphism behavior.
This study has some limitations. It’s a cross sectional
study, incapable for prospective analysis. Study groups
sample size may confer lower reproducibility. The results
of a study composed exclusively by hypertensive patients,
of a unique center, cannot be extrapolated for the general
population. Therapeutic effects and possible pharmaco-
logical interactions analysis along with the final results
were not done, once medicine therapies were not inter-
rupted or paused for ethical reasons. Genetic analysis
methodology (SNP) has limitation on the genotype -
phenotype interface comprehension: it represents part of
the genetic predisposition; and, this methodology don’t
enable the multiple numerous simultaneous genes ana-
lysis, like on genome wide association (GWA), hampering
the search of a genetic signature for polygenetic diseases
like MetS.
Table 5 Logistic regression of CVD and allele 4 association in MetS (+) and MetS (−) patients adjusted for age, sex,
smoking, DM, Col, HDL-C and LDL-C
Metabolic syndrome (+)
CVD OR CI P
Adjusted for E4 allele 1.96 1.03 - 3.70 0.03
Adjusted for E4 allele, age 2.28 1.16 – 4.47 0.01
Adjusted forE4 allele, age, sex 2.28 1.16 – 4.49 0.01
Adjusted for E4 allele, age, sex, smoking 2.45 1.23 – 4.87 0.01
Adjusted for E4 allele, age, sex, smoking, DM 2.45 1.22 – 4.90 0.01
Adjusted for E4 allele, age, sex, smoking, DM, Col 2.37 1.16 - 4.81 0.01
Adjusted for E4 allele, age, sex, smoking, DM, Col, HDL-C 2.38 1.16 - 4.87 0.01
Adjusted for E4 allele, age, sex, smoking, DM, Col, HDL-C, LDL-C 2.23 1.08 - 4.59 0.02
Metabolic syndrome (−)
CVD OR CI P
Adjusted for E4 allele 0.21 0.04 – 0.96 0.04
Adjusted for E4 allele, age 0.19 0.04 – 0.90 0.03
Adjusted for E4 allele, age, sex 0.18 0.04 – 0.87 0.03
Adjusted for E4 allele, age, sex, smoking 0.20 0.04 – 0.97 0.04
Adjusted for E4 allele, age, sex, smoking, DM 0.19 0.03 - 0.92 0.04
Adjusted for E4 allele, age, sex, smoking, DM, Chol 0.17 0,03 - 0,83 0.02
Adjusted for E4 allele, age, sex, smoking, DM, Chol, HDL-C 0.17 0.03 - 0.84 0.03
Adjusted for E4 allele, age, sex, smoking, DM, Chol, HDL-C, LDL-C 0.19 0.03 - 1.00 0.05
CVD: cardiovascular disease; DM: diabetes mellitus; Chol: total cholesterol, HDL-C: HDL-cholesterol; LDL-C: LDL-cholesterol.
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In summary, the results presented in this study show
that association between ApoE gene and CVD maybe
modulated by the presence of MetS, with an increased
CV burden observed among E4 carriers with the syn-
drome. On the opposite way, E4 carriers without visceral
obesity had a lesser prevalence of CVD. The extrapola-
tion of such observations shall be validated in a longitu-
dinal observation and a larger population study.
Methods
The study was approved by the Ethics and Research
Committee (no. 311.413/06.21.2013, Ministry of Health,
Brazil). Invited patients received explanations about
study objectives and signed Ethics and Research Com-
mittee Informed Consent. It was enrolled 450 consecu-
tive patients from the Hypertension and Cardiovascular
Metabology Integrated Center of the Kidney and Hyper-
tension Hospital, Universidade Federal de São Paulo
(UNIFESP). Of the total, 67 patients were excluded be-
cause of not having completed sample collection and
fulfilling Apo E polymorphism identification or because
of participation refusal. This way, 383 patients were di-
vided in two groups, classified by MetS presence, ac-
cording to IDF definition: Group 1: 266 patients with
MetS (MetS +) and Group 2: 117 patients without Mets
(MetS -). Patient’s data were collected by clinicalevaluation, physical exam, file reviews and laboratory
testing. Presence of cardiovascular disease (CVD) was
considered when identified on the office or on files
registry, history of stroke, peripheral vascular disease,
coronary artery disease or congestive heart failure [27].
Additionally, identification of diabetes mellitus and/or
dislipidemia among patients were determined the Ameri-
can Diabetes Association guideline [28] and the ACC/
AHA 2013 Guideline for diagnosis and treatment of dys-
lipidemia [29] definitions.
Glucose, total cholesterol and triglycerides plasmatic
concentrations were determined by automatized enzimatic
assay. HDL-cholesterol and LDL-cholesterol measures
were determined by following commercial manufacturers
specifications. Renal function was accessed by plasmatic
urea level by colorimetric-enzimatic assay and by plas-
matic creatinine level by Jaffé method. C-reactive protein
was determined by quimioluminescence imune-assay.
Analysis of apolipoprotein E gene polymorphisms
The sequence of 244 base pairs of the Apo E gene was
amplified, through PCR amplification, using the primers:
Sense: 5′-TCCAAGGACCTGCAGGCGGCGCA-3′
Antisense; 5′ACAGAATTCCGCCCCGGCCTGGTAC
ACTGCCA-3′
The PCR products were digested with the restriction
enzyme Hha I and the fragments were separated by
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ning the gel was incubated with ethidium bromide for
30 minutes and the DNA fragments were visualized UV
light. The E2, E3 and E4 alleles were analyzed and the
corresponding genotypes.
Once obtained PCR product, 10ul were subjected to
electrophoresis on 2% agarose gel stained with ethidium
bromide (0.5 uL/mL) for 90 minutes at 120 V in 1× TBE
solution. The specific amplification bands were visual-
ized under ultraviolet (UV) light and photographed for
later analysis of the polymorphism.
Groups were analyzed and compared on epidemio-
logical, clinical and laboratorial characteristics as well as
allele and genotype distribution in relation to ApoE
polymorphism. The prevalence of different alleles and
genotypes were analysed in relation to race observing
the Hardy-Weinberg equilibrium. Groups were classified
based on allele presence allowing analysis of clinical and
laboratory characteristics. Prevalence of CVD, according
to Mets presence, was analysed based on the three com-
mon alleles (E2,E3,E4) prevalence.
Statistical analysis
Data were expressed in mean and standard deviation for
variables with normal distribution. Student t test (para-
metric variables) and Mann–Whitney test (non parametric
variables) were used to access, between groups, differences
on analyzed variables. X2 test was used for proportional
comparisons. Binary logistic regression was used to
analyze the association between specific alleles manifesta-
tions of each polymorphism in relation to CVD presence.
In all tests, 0,05 or 5% was fixed as the level of nulitiy
hypotesis rejection.
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